In addition, they reported that ROX lowered the hepcidin level (WMD: −51.31 ng/ml; 95% CI: −67.88, −28.12; p <0.00001) and the ferritin and TAST levels in NDD-CKD patients, and these results were almost similar to other previous systematic reviews [42–44]. This evidence concerns the gene HAMP and chronic kidney disease.